What is Medpace?
Headquartered in Cincinnati, Ohio, Medpace operates as a premier global clinical research organization (CRO). The company provides an end-to-end suite of clinical development services, supporting clients from initial research phases through to late-stage clinical trials and final regulatory submissions. Its scientifically-driven operating model distinguishes it from competitors, allowing for high-precision execution in medical therapy development. By integrating deep therapeutic expertise with a global operational footprint, Medpace serves as a critical partner for medical device organizations and pharmaceutical manufacturers navigating the rigorous demands of modern drug development.
How much funding has Medpace raised?
Medpace has raised a total of $161M across 1 funding round:
Stock Offering
$161M
Stock Issuance/Offering (2016): $161M, investors not publicly disclosed
Key Investors in Medpace
Medpace
Undisclosed investor participating in the funding round.
What's next for Medpace?
With the recent capital injection, Medpace is positioned to further optimize its clinical trial management systems and expand its regulatory consulting capabilities. The firm is expected to leverage this financial backing to enhance its technological infrastructure, potentially integrating advanced data analytics to accelerate trial timelines. As the demand for specialized clinical research services grows, Medpace's strategic focus will likely remain on scaling its global reach and deepening its therapeutic specialization to maintain its competitive advantage in the high-stakes CRO market.
See full Medpace company page
